the author on a meticulous review of the literature. W e do, however, have som e additional com m ents to m ake with respect to this im portant subject.
First, w hile we w ould certainly agree that the absolute incidence of radiotherapy-induced sarcom as is lowÐ and that this in itself should not suf® ce to deter patients from receiving radiotherapy where indicatedÐ it is clear that sarcom as represent only a m inority of all radiation-induced neoplasm s.
2 Accordingly, readers of the review should not m istakenly infer that the risks of radiation-induced neoplasm s in general are necessarily negligible or trivial. Second, it is stated that im proved radiotherapy techniques over the past tw o decades deliver less dam age to surrounding tissues, and hence can be assu m ed to be less carcinogenic. Although this is a popular assu m ption, the well-recognized biphasic relationship betw een radiation dose and tum our induction cautions that it m ay not necessarily prove to be correct. 3 Indeed, our own observations have suggested that second tum ours tend to cluster around the ® eld edge, rather than w ithin the m ost`damaged' region of irradiation (unpublished data). T echniques to m inim ize beam scatter m ay therefore rem ain relevant despite other m odern technical im provem ents. 4 Third, certain patient subsets m ay be at signi® cantly higher risk of radiogenic second m alignancy than others, and hence less approp riately reassured by the ® ndings of the review. In particular, we suggest that young patients ( , 35 years) fall into this category 3, 4 and advise that these patients and their oncologists continue to include the hazard of second m alignancy in their therapeutic decisionm aking algorithm . 
